The present invention relates to methods for production of 2Fucosyllactose by a microbial system comprising a -1,2 fucosyltransferase (FucT2) polynucleotide and a Guanosine 5-diphospho--L-fucose (GDP-L-fucose) synthesis pathway using lactose as a substrate. Furthermore, the present invention relates to compositions comprising the microbial system.

The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with -1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.

Methods for producing oligosaccharide products such as difucosylated oligosaccharides are disclosed. The methods include culturing recombinant cells in a cell culture medium comprising L-fucose, an oligosaccharide acceptor, and a carbon source. The cells are cultured under conditions in which a first fucosyltransferase polypeptide having a first substrate selectivity (e.g., an 1-2-fucosyltransferase polypeptide), a second fucosyltransferase polypeptide having a second substrate specificity (e.g., an 1-3-fucosyltransferase polypeptide), a nucleotide sugar pyrophosphorylase polypeptide, a lactose transporter polypeptide, and an L-fucose transporter polypeptide are expressed, and in which the oligosaccharide acceptor is converted to the difucosylated oligosaccharide. Recombinant cells for use in the methods are also described.

The invention relates to a method for selective crystallization of 2-fucosyllactose (2-FL) from an aqueous solution comprising 2-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution. The aqueous solution is separated from an aqueous culture medium prior to crystallization.

The invention relates to a method for selective crystallization of 2-FL from an aqueous solution comprising 2-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.